LumiThera said March 3 that Diopsys is now a wholly-owned subsidiary. The acquisition is expected to create a complementary diagnosis and monitoring platform to LumiThera’s Valeda treatment platform.
The addition of Diopsys’ U.S. sales team will combine with LumiThera’s European Union sales team.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.